PIONeeR Project's team
WP0 – Coordination

Pr. Fabrice Barlesi
Université Paris-Saclay, Institut Gustave Roussy
Coordinator of the PIONeeR Project RHU

Dr. Marie Roumieux
Aix-Marseille Université
RHU Project Manager
Administration of the consortium, management of the RHU (scientific-regulatory-budgetary aspects, human resources), communication and dissemination in connection with the consortium and ATCG-Partners
WP1 – Clinical Studies

Dr. Pascale Tomasini
Aix-Marseille Université, AP-HM
Investigational clinical center of Marseille
Principal investigator-study coordinator of
the early phase randomized umbrella clinical trial
Co-leader du WP1
.jpg)
Pr. Laurent Greiller
Aix-Marseille Université, AP-HM
Investigational clinical center of Marseille (and satellite centers)
Principal investigator-study coordinator of the biomarkers protocol
Co-leader du WP1

Alexandra Giuliani
DRS APHM – Sponsor
Project manager of the two PIONeeR clinical studies
(regulatory documents, budget, logistics and human resources)
.jpg)
Dr. Maryannick Le Ray
DRS APHM – Sponsor
CRA-coordinator
Redaction of regulatory documents, patients
(inclusions, e-CRF)
& samples follow-up in connection with academic
and industrial analysis platforms

Pr. Julien Mazières
Hôpitaux de Toulouse-Université Paul Sabatier
Investigational clinical center of the Toulouse University Hospital (and satellite centers)
Co-principal investigator of the biomarkers protocol and of the early phase randomized umbrella clinical trial

Dr. Maurice Pérol
Centre Léon Bérard (CLB)
Investigational clinical center of the CLB Lyon (and satellite centers)
Co-principal investigator of the biomarkers protocol and of the early phase randomized umbrella clinical trial

Sylvie Chabaud
Centre Léon Bérard (CLB)
Investigational clinical center of the CLB Lyon (and satellite centers)
Co-principal investigator of the biomarkers protocol and of the early phase randomized umbrella clinical trial

Claire Cropet
Centre Léon Bérard (CLB)
Investigational clinical center of the CLB Lyon (and satellite centers)
Co-principal investigator of the biomarkers protocol and of the early phase randomized umbrella clinical trial

Dr Nicolas Ozan
AstraZeneca
Medical Director Oncology France
Link between AZ teams in the US & the UK, and the AP-HM
and RHU coordination teams (supply, regulatory and legal aspects of experimental molecules)

Dr. David Perol
Centre Léon Bérard (CLB)
Clinical Research and Innovation Department
Study design and statistical analysis of the
early phase randomized umbrella clinical trial
WP2 – Biomarkers

Dr. Florence Monville
Veracyte
Coordinator of the Biomarkers profiling program (blood, tumors, feces)

Jean Philippe Dales
Aix-Marseille Université, AP-HM
APHM anatomopathology department
Centralized collection and processing of
tumor samples from the PIONeeR protocols

Dr. Frédéric Vély
Aix-Marseille Université, AP-HM
MI/AP-HM immuno-profiling platform
Immunoprofiling of soluble and cellular biomarkers
from PIONeeR patient blood samples

Amélie Pouchin
Aix-Marseille Université, AP-HM
MI/AP-HM immuno-profiling platform
Immunoprofiling of soluble and cellular biomarkers
from PIONeeR patient blood samples

Pr. Florence Sabatier
Aix Marseille Université AP-HM
Vasculo-monitoring platform of APHM
Study of the link between immunotherapy and
the endothelial compartment in PIONeeR patients

Laurent Arnaud
Engineer – AP-HM
Vasculo-monitoring platform of APHM
Study of the link between immunotherapy and
the endothelial compartment in PIONeeR patients

Pr. Joseph Ciccolini
Aix-Marseille Université, APHM
Centre de Recherche en Cancérologie de Marseille (CRCM)- SMARTc laboratory
Clinical pharmacokinetics and toxicology department
PK-PD study and modeling

Dr. Sivan Bokobza
Manager IHC, Innate Pharma
Tissue biomarkers profiling by immuno-histochemistry

Inria – Inserm team COMPO (CRCM)
Biostatistician
Biostatistical, integrative (machine learning)
and mechanistic analyses of the PIONeeR BioMarkers protocol and
mathematical modeling of the response to immunotherapies
WP3 – New immune-checkpoint modulators candidates

Pr. Eric Vivier
Aix-Marseille Université, APHM,
Centre d’Immunologie de Marseille Luminy (CIML), Innate Pharma
WP3 co-leader

Dr. Pierre Milpied
Inserm, Centre d’Immunologie de Marseille Luminy (CIML)
Characterization of anti-tumor activity of B lymphocytes
WP3 co-leader
Co-Leader of WP3

Dr. Emilie Narni-Mancinelli
Inserm, Centre d’Immunologie de Marseille Luminy (CIML)
Evaluation of the NKP44/46 pathway in anti-tumor immunity

Pr. Daniel Olive
Aix-Marseille Université, IPC, CRCM
Evaluation of the BTLA/HVEM pathway in anti-tumor immunity
Co-Leader du WP3

Dr. Emmanuel Valentin
ImCheck Therapeutics
Evaluation of the BTLA/HVEM pathway in anti-tumor immunity

Dr. Ana Zarubica
CIPHE platform
Evaluation of the BTLA/HVEM pathway in anti-tumor immunity
Generation and immunophenotyping of transgenic mouse models
WP4 – Communication and exploitation
.jpg)
Dr. Jean Philippe Tissier-Seta
Céline Voisin
Marie Puvieux
Communication et dissémination scientifique